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Background: Radiation safety is an essential component in the treatment of patients with thyroid diseases by 131I.
The American Thyroid Association created a task force to develop recommendations that would inform medical
professionals about attainment of radiation safety for patients, family members, and the public. The task force was
constituted so as to obtain advice, experience, and methods from relevant medical specialties and disciplines.
Methods: Reviews of Nuclear Regulatory Commission regulations and International Commission on Radio-
logical Protection recommendations formed the basic structure of recommendations. Members of the task force
contributed both ideas and methods that are used at their respective institutions to aid groups responsible for
treatments and that instruct patients and caregivers in the attainment of radiation safety. There are insufficient
data on long-term outcomes to create evidence-based guidelines.
Results: The information was used to compile delineations of radiation safety. Factors and situations that govern
implementation of safety practices are cited and discussed. Examples of the development of tables to ascertain the
number of hours or days (24-hour cycles) of radiation precaution appropriate for individual patients treated with
131I for hyperthyroidism and thyroid cancer have been provided. Reminders in the form of a checklist are pre-
sented to assist in assessing patients while taking into account individual circumstances that would bear on
radiation safety. Information is presented to supplement the treating physician’s advice to patients and caregivers
on precautions to be adopted within and outside the home.
Conclusion: Recommendations, complyingwith Nuclear Regulatory Commission regulations and consistent with
guidelines promulgated by the National Council on Radiation Protection andMeasurement (NCRP-155), can help
physicians and patients maintain radiation safety after treatment with 131I of patients with thyroid diseases. Both
treating physicians and patients must be informed if radiation safety, an integral part of therapy with 131I, is to be
attained. Based on current regulations and understanding of radiation exposures, recommendations have been
made to guide physicians and patients in safe practices after treatment with radioactive iodine.
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Overview
This document presents recommendations to providehealth providers with reasoned instructions on radiation
safety for patients, their families, caregivers, and the public after
radioiodine (131I) therapy. The recommendations should help
to ensure compliance with federal regulations of the Nuclear
Regulatory Commission (NRC) and reduce the potential for
harmful radiation exposure to others, and also to recognize that
required actions may differ when attaining compliance with
existing local regulations of other jurisdictions, for example, in
Canada. Although harm from radiation exposure to personal
contacts of 131I-treated patients has not been shown, these
recommendations follow the principle of reducing radiation
exposure to levels that are as low as reasonably achievable
(ALARA). Inherent within ALARA is an acknowledgement
that even unapparent radiation injuries are cumulative, and
that, over time, small effects contribute to definitive risks.
These recommendations are derived from a review of
current practices, expert opinions, and the literature. They
are not meant to be evidence-based guidelines since there are
insufficient data on long-term outcomes on which to base
use or lack of use of any radiation exposure precautions.
The recommendations are based on data derived from rele-
vant measurements of radiation exposure, 131I clearance and
excretion, and reports of the impact of precautions in limiting
radiation exposure. They are meant to clarify safety precau-
tions necessary and helpful in complying with NRC regula-
tions and reducing doses to ALARA. They emphasize the
roles of the treating physician and the radiation safety officer
(RSO) in individualizing the precautions for each patient
while allowing the referring physician to assist in preparing
appropriate and adequate pre- and post-therapy actions. The
hierarchy of authority and responsibility for radiation safety
is delineated in Table 1. Untoward short- and long-term ef-
fects of radiation on the treated patient, such as sialadenitis,
lacrimal duct obstruction, red marrow suppression, radiation
pneumonitis, and secondary neoplasms, are not addressed.
However, breast radiation is discussed as an extension of re-
strictions on breastfeeding.
Background
In 2008, the American Thyroid Association (ATA) assem-
bled a multidisciplinary task force to formulate recommen-
dations for 131I safety precautions. The ATA Board of
Directors desired that these recommendations reflect all spe-
cialties involved with radioiodine treatments and safety for
thyroid patients, their families, caregivers (a term that includes
roommates and friends), and the public. They appointed rep-
resentatives from the relevant disciplines, including Nuclear
Medicine, Radiation Safety, Medical Physics, Endocrinology,
and Endocrine Surgery. Liaisons from the Clinical Affairs and
Public Health committees also assisted the process. Funding
was derived solely from the general funds of theATA. The final
document has been approved by the ATA Board of Directors
and officially endorsed by the: Academy ofMolecular Imaging
(AMI), American Association of Endocrine Surgeons (AAES),
Table 1. Hierarchy of Authority and Responsibility for Radiation Safety in Treatment
of Patients with Radioiodine (131I)
Nuclear Regulatory Commission (NRC)a
 Established by U.S. Congress
 Authority
* Establishes policies and regulations.
* Grants licenses to institutions and physicians to treat patients with radioiodine-131.
 Responsibility
* Ensures radiation safety for patients, families, caregivers, and the public.
* Issues instructions regarding new policies and regulations.
* Receives reports of medical events, that is, breaches in radiation safety.
 The Advisory Committee on the Medical Uses of Isotopes (ACMUI) advises NRC on policy and technical issues that arise
in the regulation of the medical uses of radioactive material in diagnosis and therapy. www.nrc.gov/about-nrc/
regulatory/advisory/acmui.html
In ‘‘Agreement States,’’ agencies are established by state governments to monitor radiation safety and report to NRC. In other
states, the NRC directly oversees observances of radiation safety.
Radioiodine Treatment Teams (for licensure and reports: www.nrc.gov/10CFR 35.190)
 Radiation Safety Officer (RSO)
* Develops and oversees treatment protocols for patients with usual radiation safety risks.
* Provides specific advice for patients with unusual safety risks.
* Reports medical events to State Agency or to NRC.
 A Radiation Health Physicist may bridge the responsibilities between RSOs and Treatment Prescription and
Implementation Group.
 Duties of Treatment Prescription and Implementation Group (consists of physicians and clinical support staff )
* With RSO, create treatment protocols for patients with usual radiation safety risks.
* With RSO, plan specific treatments for patients who may require additional safety precautions.
* Deliver oral and written advice specific to each patient.
* Obtain written consent for therapy by patient or guardian.
* Prescribe therapies.
* Respond to medical events observed or reported.
* Report to, discuss with, RSO all medical events in radiation safety.
aNRC also regulates radiation safety through specific guidance programs for other organizations such as industrial radiography,
commercial radiopharmaceuticals, and nuclear reactors.
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AmericanAcademy ofOtolaryngology-Head andNeck Surgery
(AAO-HNS), American College of Nuclear Medicine (ACNM),
American Head and Neck Society (AHNS), Endocrine Society
(ENDO), European Society of Endocrinology (ESE), Interna-
tional Radiation Protection Agency (IRPA), Latin American
Thyroid Society (LATS), and Ukrainian Association of Endo-
crine Surgeons (UAES). The American College of Surgeons
(ACS) and the American Congress of Obstetricians and Gy-
necologists (ACOG) acknowledge support of the document.
The overall goal of these recommendations was to limit
radiation exposure from patients treated with 131I to family
members, caregivers, and the general public, consistent with
ALARA and NRC regulations. The task force recognized that
several of the precautions traditionally thought to be neces-
sary offered little benefit or protection from radiation expo-
sure, whereas others that were often overlooked served to
reduce exposure. They also recognized the critical need of
individualization in providing instructions so as to ensure
reductions to ALARA for those involved. Individuals differ
not only in their social situations but also in the activities of
131I received and rates of clearance from the body. The task
force acknowledged that the RSO at each treating facility is
critical in treatment planning and execution and should be the
final arbiter of precautions for any given patient. However,
clinical evaluation and preparation of the patient for the 131I
treatment often precedes the encounter with the RSO. A dis-
cussion of patient-specific radiation safety precautions should
also be part of the shared decision-making with the patient
and the referring and/or treating physicians and should allow
the patient to select the best timing for 131I treatment and to
make appropriate preparations at home and at work.
In the United States, the NRC replaced the Atomic Energy
Commission in regulating unsealed sources of radioactivity
(Energy Reorganization Act 1974). In 1997 and in 2009 up-
dates (1), the NRC changed its pre-1997 release requirements
for patients treated with 131I from an ‘‘activity-based limit,’’
the amount administered expressed in millicuries (mCi) or
megabecquerels (MBq) to a ‘‘dose-based limit,’’ the absorbed
dose expressed in roentgen equivalent man (rem) or sieverts
(Sv). The resultant ‘‘Patient Release Criteria Rule’’ allows re-
lease of treated patients from control of the treating facility
with higher levels of radioactivity than previously permissi-
ble. This removed the restrictions that mandated a hospital
stay in isolation for patients treated with33mCi (1221MBq)
of 131I. Others deemed this change in release criteria unwar-
ranted, and submitted a petition (2) to the NRC requesting
that the ‘‘Patient Release Criteria Rule’’ be reversed. The NRC
invited public comment regarding this petition, and the ATA
submitted a response supporting the established Release
Criteria Rule. The Rule was upheld and remains in effect.
The current regulations are less restrictive than those imposed
upon 131I therapy practices in some other nations; despite this,
there is no evidence that safety has been compromised, even as
the care of the patient was made more efficient and economical.
On the other hand, patients and the public remain concerned
about radiation exposure from the current practices (3).
Significant variability in the instructions for 131I therapy
precautions provided to patients by ATA members and
health-care providers, in general, became apparent when the
ATA began to gather this information. A subsequent survey
of ATA members about their institutions’ 131I safety precau-
tions confirmed the existence of substantial differences in
patient instructions (4). Further, even within some institu-
tions, there was disparity in radiation safety instructions
provided by the referring physician, the Nuclear Medicine
Department, and/or RSO. As part of this survey, actual pa-
tient instruction handouts were solicited from respondents;
these were reviewed, evaluated in detail, and found to range
from quite proscriptive to relatively lax. Additionally, there
were examples of direct contradiction between sets of in-
structions: for example, one advised ‘‘use disposable utensils’’
and another ‘‘to not use disposable utensils.’’ Thus, therewas a
need to clarify which safety precaution instructions best attain
ALARA, comply with the NRC regulations, and achieve pa-
tient instruction uniformity so that adherence could be max-
imized and stress and confusionminimized. The results of the
Survey were reviewed in an accompanying editorial (5).
Methods
Review of regulations
Recommendations by the International Commission on
Radiological Protection (ICRP)* sanction licensed facilities to
release a patient treated with 131I from their control as long as
the radiation exposure to any other individual (generally, a
family member) encountering the patient will likely not exceed
5mSv (500mrem) per annum, and the radiation dose to a child,
a pregnant woman, or an individual not involved in the care of
the patient will not exceed 1mSv (100mrem) per annum (25).
According to NRC regulation 10 CFR 35.75, if any individual
is likely to receive more than 1 mSv (100mrem), then the re-
leased patient must be provided with verbal and written in-
structions thatwillmaintain doses to other individuals as lowas
reasonably achievable. Patients may not be released if, despite
precautionarymeasures, exposurewill exceed5mSv (500mrem)
(15).NRC Regulatory Guide 8.39 (6) and updated guidance in
NUREG 1556 v.9 (7) provide licensed facilities with informa-
tion on how to implement the ‘‘Patient Release Criteria Rule.’’
The current NRC Patient Release Criteria allow most pa-
tients to be treated with 131I as outpatients (1). The regulations
apply to all patients who are treated with unsealed radioac-
tivity, including 131I for thyroid cancer, hyperthyroidism, and
goiter. When outpatients who were treated for thyroid can-
cer and hyperthyroidism and their families were instructed
in radiation safety, measurements demonstrated that radia-
tion exposures within the homes did not exceed regulations
in comparable studies performed in the United States (8),
Canada (9), and Brazil (10).
Radiation health physics
Most of the radiation exposure from patients treated with
131I arises from high-energy gamma rays (photons). Three
variables determine the amount of radiation a person receives
from a treated patient: the retained radioactivity in the pa-
tient, the distance from the patient (radiation levels decrease
with square of the distance from the source), and the duration
of exposure (see Occupancy Factor (OF) under Definitions
*ICRP (www.icrp.org) is an independent, international organi-
zation comprised of leading scientists and policy makers in the
field of radiological protection. ICRP provides recommendations
and guidance on all aspects of protection against ionizing radia-
tion, but has no regulatory authority in the United States.
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below). The retained radiation activity in the patient is a
function of several factors, including, but not limited to, (i) the
administered activity, (ii) the mass and function of thyroid
tissue as reflected in the concentrations of serum free T4 and
thyrotropin (TSH), (iii) the radiopharmaceutical, and (iv) the
patient’s hydration status and renal function. Therefore, the
cumulative external exposure from a patientwho has received
a given activity of 131I will vary substantially among thyroid
cancer patients who are hypothyroid or euthyroid at the time
of treatment (11) and among hyperthyroid patients (12).
Compared to those with hyperthyroidism, thyroid cancer
patients usually receive larger initial 131I activities, but, lacking
a thyroid gland, retention declines more rapidly through uri-
nary excretion, and especially when euthyroid patients are
prepared for treatment with recombinant human TSH rather
than by hormone withdrawal (11). Hyperthyroid patients re-
tain a greater percentage of radioactivity (more is sequestered
in the thyroid gland) and also manifest higher levels of circu-
lating radioiodinated thyroid hormones. The effective half-life
of 131I in a hyperthyroid gland is usually about 5 days (12).
Another potential radiation exposure pathway is ingestion
of 131I excreted/secreted by the treated patient. The majority
of the excretion of radioiodine occurs via the urine; small
amounts are present in stool, saliva, and other body fluids.
Contact with areas contaminated with excreted or secreted
131I from a treated patient could be a source of ingested 131I.
This is a special concern for young children, whose thyroid
glands (13) and other tissues such as breast (14) are more
sensitive to radiation. Therefore, ICRP recommends fol-
lowing stricter precautions to further reduce radiation ex-
posure to fetuses, children, and the general public (25).
Definitions in regulatory documents
and calculations of radiation exposure
Default administered radioactivity. According to the 1997
report (6), patients may be releasedwhen 131I retained activity
is at or below 33mCi.
Equivalents of administered activity are as follows:
1mCi¼ 37MBq and 1MBq¼ 0.027mCi.
Default measured dose rate values. A licensee may re-
lease patients, regardless of administered activity, using dose
rate measurements and TEDE (total dose effective equivalent
inmrem ormSv) tomeet NRC criteria for release. TEDE tables
should be developed (usually with the aid of an RSO) when
exposure rates are likely to be high and especially for the first
8 hours after the patient is released and during which time
safe distances from the patient may be difficult to sustain.
Patients may be releasedwhen the 131I measured dose rate is
7mrem per hour (h) at 1m as measured by a dose rate meter
(6). As noted above, patients also may be released when the
TEDE of 131I is unlikely to exceed 500mrem (5mSv). If 100
mrem (1mSv) may be exceeded in any person, pertinent
written andverbal precaution instructions are required (1,15).
Patient-specific calculations. A patient-specific calcula-
tion takes into account the administered 131I activity, its phys-
ical half-life and exposure rate constant, OFs (see below),
effective half-lives, and thyroid uptake fractions. The resultant
dose equation yields 0.17mremh1mCi1 at 1m (16,17), where
33mCi gives a dose rate of 5.6mrem/h at 1m from a patient.
The required information may be found in a TEDE table, a
supplement, that provides mrem (mSv) as a function of ad-
ministered activity and contact hours at 1m. In examples with
assumed values for the variables, calculations demonstrated
that patients could be released without exceeding applicable
dose limits after treatment with 57mCi (3177MBq) for hyper-
thyroidism and 150mCi (5550MBq) for thyroid cancer (7).
Distance and time estimations. Dose rates have been es-
tablished for a distance of 1m from a radiation source. To
facilitate understanding by the patient and family members,
1m is approximated to ‘‘>3 feet,’’ and to help ensure safety,
family members and caregivers of a treated patient are ad-
vised to remain well beyond 6 feet as much as possible. The
days (24 hours cycles) when a patient may expose others to
doses exceeding the foregoing limits noted above is the ‘‘re-
stricted time or period.’’
Occupancy factor. For an 131I-treated patient who arrives
home, the OF is usually 0.25, which means that an individual
will be exposed to a patient treated with 131I at 1m 25% of the
time, here termed ‘‘daytime restriction.’’ The assumedOF for a
person sleeping with a patient is 0.33, and, because sleeping is
assumed to be at a distance of 0.3m, exposure is thereby in-
creased and the days (24 hour cycles) containing ‘‘nighttime
restriction’’ will generally exceed the limits of daytime re-
striction (Table 2A-1, A-2).
Annotated references, including additional citations, can be
found in the Supplementary Data (available online at
www.liebertonline.com/thy).
Results and Discussion
Role of the RSO
All 131I treatments must be prescribed by a provider li-
censed as an authorized user and thus trained in adminis-
tration of radiopharmaceuticals. Radiation safety precautions
for radionuclide therapy protocols will be created and over-
seen by the RSO. Additional or individualized patient-specific
precautions will also be developed by the RSO as needed
(Table 1). A Radiation Health Physicist may be included in the
Radioiodine Treatment Team as liaison between the RSO and
the Treatment Prescription and Implementation Group.
Individualization is stressed in predicting, calculating, and
measuring the retained activity in each patient.
It is essential that radiation safety recommendations be
discussed with each patient as soon as treatment with 131I is
considered. A checklist (Table 3) provides a tool to systemati-
cally evaluate the patient, identify potential exposure risks,
and determine the suitable treatment setting. The required
precautions will often influence the choice and timing of 131I
therapy. Preparing the patient, caregivers, and employers en-
sures familiarity with the recommendations and reduces con-
cerns associated with radiation treatments. Table 4 includes a
spectrum of advice to patients. By editing through cross-outs
and additions, advice can bemade specific for a patient; itmust
be given verbally as well as in writing so as to enable the
patient to ask questions and clarify any misunderstandings.
Reproduction considerations
Recommendation. Patients should be advised in advance
that pregnancy is a contraindication to 131I therapy, and they
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Table 2. Examples of Precaution Requirements AND RECOMMENDATIONS After Treatments with 131I
2A. Restricted Periods
2A-1. Hyperthyroidism [Assumes 50% uptake by thyroid, with effective T1/2 of about 5 days (12)]
mCi (MBq) administered
10
(370)
15
(555)
20
(740)
30
(1110)
Nighttime restrictions Days/24-h cycles
Sleep in a separate (6-feet separation) bed from adults for days shown. 3 6 8 11
Sleep in a separate bed from pregnant partners, infant, or child for days shown. 15 18 20 23
Daytime restrictions
You may return to work after days shown. 1 1 2 5
Maximize your distance (6 feet) from children and pregnant women
for days shown.
1 1 2 5
Avoid extended time in public places for days shown. 1 1 1 3
2A-2. Thyroid carcinoma/remnant ablation [Assumes that disappearance of 131I is biexponential with early effective T1/2 of about 0.76 days,
and 2% uptake in remnant with effective T1/2 of about 7.3 days (7). Consider formal dosimetry (18) for larger administered doses given to
patients with functioning carcinoma. 131I kinetics in euthyroid patients stimulated by recombinant human thyrotropin may differ from
those used here (11)]
mCi (MBq) administered
50
(1850)
100
(3700)
150
(5550)
200
(7400)
Nighttime restrictions Days/24-h cycles
Sleep in a separate (6-feet separation) bed from adults for days shown. 1 1 2 4
Sleep in a separate bed from pregnant partners, infant, or child for days shown. 6 13 18 21
Daytime restrictions
You may return to work after days shown. 1 1 1 1
Maximize your distance (6 feet) from children and pregnant women for days shown. 1 1 1 1
Avoid extended time in public places for days shown. 1 1 1 1
2B. Duration of Safe Travel by Public Transportation (Bus, Air, etc.) [Assumes 100mrem limit and 0.3m distance. Other assumptions are
as in Table 2A-1 and 2A-2]
2B-1. Hyperthyroidism
mCi (MBq) administered
10
(370)
15
(555)
20
(740)
30
(1110)
Travel time (hours) without exceeding regulatory dose limit
Day (24-h cycles) 0 (beginning with treatment) 5.9 3.9 2.9 2.0
Day (24-h cycles) 1 9.2 6.1 4.6 3.1
Day (24-h cycles) 2 13.0 8.7 6.5 4.3
Day (24-h cycles) 3 – 10.6 8.0 5.3
2B-2. Thyroid carcinoma/remnant ablation
mCi (MBq) administered
50
(1850)
100
(3700)
150
(5550)
200
(7400)
Travel time (hours) without exceeding regulatory dose limit
Day (24-h cycles) 0 (beginning with treatment) 1.2 0.6 0.4 0.3
Day (24-h cycles) 1 3.0 1.5 1.0 0.8
Day (24-h cycles) 2 7.2 3.8 2.5 1.9
Day (24-h cycles) 3 15.0 7.5 5.0 3.8
Day (24-h cycles) 4 – 15.0 10.0 7.5
Examples should be modified to meet local and specific patient needs. These examples are based on dose rate of 0.17mrem h1mCi1 at
1m (16,17), 500mrem per year for family member and caregiver, 100mrem for pregnant women, children, and the public, and Occupancy
Factors for adults of 0.25 except for sleeping 0.33. Resumption of sleeping with a partner assumes a distance of 0.3m (7).
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should take measures to prevent pregnancy once treatment
with 131I is planned. Pregnant women should never be treated
with 131I, and a pregnancy test must be performed before the
time (usually within 72 hours) of treatment in all women,
from menarche to 2 years after menopause, who could be-
come pregnant. Pregnancy should be delayed for at least
6 months after radioiodine therapy, a delay based on the need
to normalize thyroid levels for a successful pregnancy and
healthy infant development, and to ensure that additional
radiation treatment is not imminent.
There are exceptions to the requirement for a pregnancy
test, but there must be incontrovertible evidence that preg-
nancy is impossible, for example, surgical hysterectomy.
Discussion. There is a delay between conception and the
sensitivity of tests to detect pregnancy. Blood and urine
Table 3. Eligibility Assessment Checklist
It is incumbent upon the Radioiodine Treatment Team and the patient to agree upon a plan that, by environmental and
population assessments and by calculations, will not put others at risk of radiation exposure as identified in NRC regulations
and ICRP recommendations.
Absolute contraindications to 131I therapy (pregnancy and breastfeeding)
1. Determine absence of pregnancy by:
___Pregnancy test within 72 hours prior to treatment, or
___Historical evidence of hysterectomy, or
___No menses for 2 years and >48 years old, or
___Other incontrovertible evidence for absence of pregnancy.
2. Determine absence of lactation and/or breastfeeding:
___By interview and/or clinical examination, or
___If uncertain and treatment is needed urgently, recommend 123I scan to assess breast concentration of radioiodine.
REMEMBER, Breastfeeding or pumping must not be resumed after 131I therapy.
Consider inpatient 131I therapy and consult RSO when
1. Proposed 131I dose is
___200mCi (7400MBq) or
___TEDE, despite written instructions, is likely to exceed, 0.5 rem (5mSv) to an adult family member or caregiver, or to
exceed 0.1 rem (1mSv) to a pregnant woman, child or a member of the general public.
2. The patient is unable to comply with oral and written instructions and therefore will require special planning because of:
___Incontinence issues;
___Requires help with devices such as Foley catheters, peritoneal dialysis equipment, feeding tubes, etc.;
___Cognitive/psychiatric limitations;
___Travel/housing limitations;
___Other limitations (name).
Information gathering for radiation safety precaution planning
Travel: To home on the day of treatment or subsequently:
___Patient will drive alone and is competent to do so.
___Patient plans to use private car with a driver, or taxi, or car service. The patient must sit alone in a back seat >3 feet
from the driver. If travel requires taxi or duration is over 2 hours, consult RSO.
___Patient is limited to travel by bus, train, subway, ferry, or other public conveyance. This option requires a calculation of
TEDE for other individuals and approval by the RSO (see Tables 2B-1 and 2B-2).
Home: Living arrangements (relationship, age and gender of each household member)
For all household members, patient must be able to stay >6 feet away most of time (care givers may approach 3 feet up to
25% of the time.)
Special Household Situations. Check all that apply; provide appropriate information and make an alternate arrangement:
___Household member is pregnant, and the patient cannot stay at least 6 feet away all of the time.
___Household member(s) are under the age of 16, and the patient can’t stay at least 6 feet away all of the time.
___Patient is responsible for the care of an infant or young child.
___There is not sufficient space to maintain >6 feet distance from others.
___Patient unable to sleep alone during nighttime restricted period.
(Consult RSO and/or consider admission.)
___Patient must share a bathroom with others. (Special home arrangements: Emphasize instructions in Table 4, Step 4,
General Recommendations).
Work/School: Employment or school status, including required activities, environment, contacts with co-workers or fellow
students, and arrangements to commute to work/school. From all co-workers or classmates patient must be able to
maintain at least 6 feet distance at all times except for momentary encounters.
Special Work/School Situations:
___Associated with children <16 years of age. If patient cannot stay >6 feet away, delay return to work
___Associated with pregnant women. If patient cannot stay >6 feet away, delay return to work.
___Food preparation for others. Get special instructions from RSO/Radioiodine Treatment Team.
Commuting to work or school
___Car pooling or public transportation for periods of daytime restriction: make alternate arrangement or obtain special
instructions from RSO.
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Table 4. Safety Instructions for Patients Receiving Radioiodine Treatment
To be given verbally and in writing and edited as appropriate for the patient.
Dear Patient, (name)________________ Date:________
With regard to your radioiodine therapy, please consider the following.
Step 1: Talk with your doctor or a member of the Radioiodine Treatment Team about
Why treated women must
* Avoid pregnancy for a period of time and
* Not breastfeed.
When treated men can consider fathering a child.
Who will give you the radioiodine therapy, and where and when this will happen.
Step 2: Make preparations before treatment and talk with your doctor or a member of the Radioiodine Treatment Team about
the following specific items;
Obtaining
* Wipes and/or toilet paper that can be flushed down the toilet;
* Disposable gloves if others will be helping to take care of you;
* Heavy duty (doubled if possible), leak proof, specified plastic trash bags for tissues, paper towels and other things that
may be contaminated and trashed;
For your travel:
* If you are well enough, it is best to drive yourself;
* If you ride with someone else, confirm she is not pregnant, and maintain a distance of >3 feet (use the back seat on
opposite side of the driver);
* When and where you can take necessary trips;
* When it is safe to use public transportation;
For home:
* Living or working with a pregnant woman;
* Associations with children;
* Inability to control your urine or bowels;
* Using special medical equipment, such as catheters, ostomy bags, or anything that could be contaminated by your
body fluids;
* Getting sick easily (throw up or get woozy);
* Not being able to go directly home; arrangements must be made through your treatment team; hotel and motel stays
are not recommended.
Step 3. Your doctor or member of the Radioiodine Treatment Team will discuss with you the following items and fill in the
number of days related to each.
________ Days that you need to stay >3 feet away from your adult family members and caregivers for at least 18 hours a
day, and at least 6 feet away as much as possible.
________ Days that you need to stay >6 feet away from babies, children younger than 16 years old and pregnant women.
________ Days that you need to stay away from work and close contact with others in public places (movies, shopping,
etc).
________ Days that you need to stay away from school or day-care (includes both teachers and students).
Step 4. Recommendations for after therapy
At home
Specific recommendations. Ask your doctor for the number of days to:
* Sleep alone in a bed that is >6 feet away from another person, and, if possible, use a separate bedroom or sleeping
room all by yourself;
* Not kiss anyone;
* Not have sexual activity;
* Move your bowels every day and use a laxative if you need help;
* Empty your bladder (urinate) every hour or so during the day of, and day after your radioiodine treatment; follow
your doctor’s advice on how much to drink;
* Use wipes (preferably flushable) to clean the toilet seat after use; men should sit down to urinate and use wipes to
remove splatter of urine; wipe yourself dry after urinating so that you do not drip;
* For a phone you share with others, after use, wipe off the mouthpiece, or, while using, cover the phone with a plastic
bag that, after use, is placed in specified plastic trash bag.
General Recommendations especially for patients sharing a bathroom
* Flush the toilet after each time you use it; flush toilet paper and wipes;
* Always wash your hands well after using the toilet;
* Rinse the sink and wash your hands after brushing your teeth to wash away the saliva (spit);
* Do not share your toothbrush, razor, face cloth, towel, food or drinks, spoons, forks, glasses and dishes;
* Shower every day for at least the first 2 days after your treatment;
* Do not cook for other people. If cooking is necessary, use plastic gloves and dispose of in the specified plastic trash bag;
* Wash your dishes in a dishwasher or by hand; it is better not to use disposable (throw away) dishes which must be put
into a specified plastic trash bag;
(continued)
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pregnancy tests are usually positive at about 1 week of ges-
tation or as stated in the package insert. Current urine and
serum tests are of nearly equal sensitivity. There may be
some treated patients who later discover that they were
pregnant at or near the time of the 131I dosing. In these
situations, the pregnancy will be in a very early stage, and
before the ability of the fetal thyroid gland to concentrate
iodide, which commences about 10 to 12 weeks of gestation
(19,20). However, there is still a concern for fetal whole-
body radiation exposure. Such cases should be handled on a
case-by-case basis, and a qualified medical physicist should
estimate the absorbed radiation dose to the fetus. In a lit-
erature review of patients treated with 131I during preg-
nancy, each of 13 patients who received as little as 15mCi
after the 10th week of gestation gave birth to babies with
hypothyroidism or cretinism; 4 patients who were treated
before the 10th week delivered normal infants (20). If a
pregnant woman is treated, data must be provided to her
obstetrician, and, in an expedited fashion, the patient must
be counseled on possible pregnancy outcomes and treat-
ment options.
In a meta-analysis, no evidence was found that 131I
treatments impaired fertility (21). In another meta-analysis,
radioiodine therapy for thyroid cancer in young men has
been associated with transient testicular dysfunction ex-
pressed as elevated serum FSH levels for up to 18 months
after treatments, and some articles reported low sperm
counts exceeding 1-year duration (22). Limited data indi-
cate that fathering a child within 3 months of radiation
exposure is not associated with an increase in congenital
anomalies or fetal loss, and there is no evidence of long-
term reduced fertility. However, men should be advised
that full fertility may not occur until after 1 year, and at-
tempts to produce pregnancy should best await a time
when they are fully recovered from 131I therapy, a period of
at least 3 months.
Table 4. (Continued)
* Try to flush any tissues or any other items that contain anything from your body, such as blood, down the toilet; items
that cannot be flushed, such as menstrual pads, bandages, paper/plastic dishes, spoons and forks and paper towels
should be put in the specified plastic trash bag;
* Wash your underwear, pajamas, sheets and any clothes that contain sweat, blood or urine by themselves; use a
standard washing machine; you do not need to use bleach and do not need extra rinses;
* Have any one who helps you clean up vomit, blood, urine, or stool wear plastic gloves; the gloves should then be put
in the specified trash plastic bag.
Trash Recommendations
* Keep the specified plastic trash bags separate from other trash; keep the bags away from children and animals;
* A member of your Radioiodine Treatment Team will tell you how and when to get rid of the specified plastic trash
bag; you may be asked to bring the bag back to your treatment facility, or, after 80 days, the bag may be removed as
other trash bags.
Pets
* Usually pets will not receive enough radiation to harm them. But do not sleep with pets (ask your doctor for how long)
since your saliva, perspiration or other secretions may be carried away by the pet.
Outside the Home. Ask Your Doctor or a member of the Radioiodine Treatment Team when:
* It will be safe to eat out, go shopping and attend events such as religious services, parties and movies;
* You will be able to return to work and to care for or teach others;
* It would be safe to donate blood;
* Special or longer distance travel is possible (Note: For up to 3 months or more following radioiodine treatment you
may set off radiation detectors at: national borders, airports, bus and train stations, tunnels, bridges, trash collection
sites and even your place of employment); a member of your Radioiodine Treatment Team will issue you a letter or
card describing the therapy and the phone number of a person knowledgeable about your treatment (usually at the
treating facility) in case local law enforcement agents need to check on this information; you should keep the letter or
card containing the information with you whenever you are traveling for at least 3 months.
Emergency Care
* You will get an information card or letter at the time of your treatment that will show the date, type and amount of
radioiodine that you were treated with; carry this card with you at all times for at least 3 months following your
treatment;
* If you are in a traffic accident or any other medical emergency during the first week after your treatment, you should
show this card to the medical people to let them know about the date and dose of your radioiodine treatment.
IMPORTANT INFORMATION FOR PATIENTS ON RISKS OF RADIATION
Radiation exposure to others should always be As Low As Reasonably Achievable, a goal often abbreviated as ALARA. If
you follow the above advice, the radiation from you to others is likely to be less than what they receive from radiation in
nature over a year’s time.
Please phone us if:
 you have any questions, and particularly if
 any of the above instructions cannot be followed and/or if
 you see anything that may have accidentally or unavoidably increased exposure of others to radiation.
We welcome your input on how we can improve our methods and advice to patients.
Phone: _______________________________________
Sincerely yours,
______________________________________________
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Breastfeeding
Recommendation. Women who are lactating or have re-
cently stopped breastfeeding should not be treated with 131I
since the lactating breast concentrates a substantial amount of
iodide. Breastfeeding must be stopped at least 6 weeks before
administration of 131I therapy, and a delay of 3 months will
more reliably ensure that lactation-associated increase in
breast sodium iodide symporter activity (23) has returned to
normal. If the 131I treatment is urgent or there is concern re-
garding residual breast uptake, an 123I scanwill detectwhether
breast concentrations of radioactivity greater than normal
(substantially above background) should impose a delay in
therapy. Involution of lactating breasts is variable as demon-
strated in 123I scans; in a small series, there was evidence that
bromocriptine accelerates involution (24); however, this agent
must be prescribed in the ‘‘off label’’ mode. Breastfeeding
should not be resumed after administration of 131I. Breast-
feeding can be safely undertaken after future pregnancies.
Discussion. Breastfeeding should be discontinued for
two reasons. The first and most critical is to prevent 131I in the
milk from reaching the infant and particularly the infant’s
thyroid gland. The second reason is to limit radiation of the
breast tissue, which, via the increased expression of sodium
iodide symporter during lactation, promotes 131I concentra-
tion. If a woman is intermittently breastfeeding or if there is
obvious milk still present despite cessation of nursing, then
131I treatment should be delayed.
Time and distance
Recommendations. Dose rate calculations from pre-
dicted body retentions of 131I determine when the dose at 1m
will be less than the regulatory limit for patient release. Dur-
ing the period in which exposure at 1m will exceed this limit
(i.e., daytime restriction), adult family members and care-
givers should remain >6 feet away except during the 25% OF
time at 1m. Invoking the ALARA principle, all individuals
should stay at least 6 feet away from each treated patient as
much as possible throughout the restricted period. Adult
family members or caregivers may be closer than 1m for brief
periods, preferably for only minutes. The duration of these
distance restrictions depends largely on the amount of thyroid
tissue and the rate of clearance of retained activity that will
be assessed by a licensed practitioner in consultation with
the RSO.
Table 2A-1 and 2A-2 give examples of days (24-hour cycles)
required for compliance with 1-m distance restrictions. These
data are based on NRC guidelines, published rates of radia-
tion exposure at 1m, and published rates of 131I clearance in
hyperthyroid and in hypothyroid cancer patients. Similar ta-
blesmay be constructed for patients whowill receive different
activities of 131I and/or who are euthyroid on replacement or
suppressive therapy with thyroid hormone (and are stimu-
lated by recombinant human TSH).
Constraints on time and distance apply to travel, home,
work, school, and social activities.
Post-therapy travel
Recommendations. Optimally, when there is no physical
or other impairment, the patient should drive alone in a pri-
vate car. For this situation, there is no time or distance limit
except that the patient should drink sufficient fluids to ensure
frequent urination and thereby reduce radioiodine in the
bladder. Advance planning should include safety in the use of
restrooms during the travel home.
If the patient must ride or drive with another person, then
time and distance constraints apply. If the person in the ve-
hicle is also a member of the patient’s household, the allow-
able exposure during the car trip may limit subsequent
exposurewithin the home. TEDE tables should be constructed
to determine how radiation safety limits the duration of the
trip with another occupant; the minimum separation distance
should be >3 feet, for example, one sitting in the driver’s seat
and the other in the passenger-side back seat. Use of a larger
vehicle, such as a van, would permit further separation and
consequently a longer period of safe travel. Again, frequent
emptying of the patient’s bladder should be emphasized but
with afore thought to safety in the use of restrooms.
Public transportation or mass transit should be avoided
throughout restricted periods as recorded in Table 2B-1 and
2B-2. Special circumstances are in the purview of the RSO and
will be based on treatment characteristics and also patient
reliability. In a different analysis, International Commission
on Radiological Protection has published recommendations
(25) that allow use of public transportation by some patients
treated for hyperthyroidism: the patient may use this trans-
portation for 0.5 hour after 22mCi (800MBq) with progres-
sion to 3.5 hours after 5.4mCi (200MBq).
Radiation detectors at ports of entry. The International
Atomic Energy Agency notes that when releasing patients
containing radionuclides with measurable gamma ray emis-
sions, unanticipated detection of radiation from such people is
possible, or even likely, by radiation-detection systems at
places of employment, international borders, airports, train
stations, bridges, tunnels, and other areas. With current
technology, it is possible to detect 131I activity as little as
0.01MBq of 131I at 2 to 3m (26). It is possible that patients
treated with 131I could trigger alarms at such detection sites
for 95 days or longer after treatment (26,27). Although the
amount of 131I does not endanger the public, if detected, it
likely will lead to time-consuming explanations and docu-
mentations.
If, within 4 months of receiving 131I therapy, travel is
planned, particularly across international borders or via air-
ports, tunnels, and/or over bridges and wherever inspection
is likely, a form should be provided to the patient. The form
should specify the date of treatment, the radionuclide and
activity administered, the treating facility, and the name and
telephone number of a contact individual knowledgeable
about the case.
Post-therapy living situations
Hotel/motel accommodations. A stay in a hotel or motel
is not recommended after treatment with 131I. Without spe-
cific environment assessments and dose-rate calculations,
hotels and motels should be avoided for the periods of day-
time restrictions in Table 2A-1 and 2A-2. The RSO should be
consulted if a patient must travel a substantial distance after
treatment, requires additional follow-up imaging, or cannot
travel home without an overnight stay.
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Home accommodations. The occupational factor for 8
hours of sleep is 0.33 and the anticipated distance between
sleeping partners is 0.3m. Patients should sleep alone and at
least 6 feet away from any other individual throughout
the nighttime restricted period. Use of a separate bedroom or
sleeping area would be best. Table 2A-1 and 2A-2 give
examples of restriction periods and demonstrate the more ex-
tended nighttime restricted periods for sleeping with another.
If there are pregnant women, infants, and children under 16
years of age in the home, arrangements should ensure that a
distance >6 feet can be maintained between the patient and
these occupants for the entire restricted time. Input from the
RSO should be sought early in the planning process to adapt
post release radiation precautions to the patient’s home con-
figuration. Having a treated parent staying in the home with
children is often problematic due to children’s needs and de-
sires to be near the treated parent. Special arrangements should
be made for children to stay with relatives or friends; alterna-
tively, the treated parent may stay with relatives or friends
where children and pregnant women are absent.
Work/school accommodations. Upon return to work or
school, constraints in time and distance are similar to those in
the home environment, with special emphasis on preventing
exposure to pregnant women and children.
Personal hygiene
Hygiene precautions are meant to reduce not only external
exposure but also ingestion of 131I from secretions and ex-
cretions of the patient.
Urine. Urine is the primary excretion route for 131I and is
maximal during the first 48 hours after treatment. Sufficient
fluid (3–4 L/day) should be consumed to enable frequent
urination but care should be taken for hypothyroid patients,
and particularly those who are elderly, because there is re-
duced free-water clearance that may lead to hyponatremia.
Diuretics should be discontinued if possible. Patients should
adjust their fluid intake to enable voiding every hour while
awake for the first day after treatment and continue to void
often for the next few days to reduce radiation exposure to the
urinary bladder and adjacent internal organs.
The following recommendations are for all restricted peri-
ods. Both men and women should sit for urination to avoid
splatter of radioactive urine. Patients should wipe themselves
dry to avoid dripping and contamination of clothing. Flush-
ing the toilet twice after each use is often recommended, but,
unless small children or animals gain access to the toilet, there
is little additional benefit from this. However, wiping the rim
of the toilet with damp toilet paper (or a flushable wipe) that is
subsequently flushed may remove a source of radiation that
can reach others. This is especially important when a bath-
room is being shared with household members or a public
restroom is used. Handwashing after using the toilet should
be emphasized.
If urinary incontinence is anticipated, then discussion with
the RSO during the planning stages is important, and the
duration of the recommendations should be determined on an
individual basis. Incontinence pads must be disposed of in a
heavy duty (preferably double) plastic trash bag (hereafter
referred to as specified trash bag) devoted to radiation waste
(see below and Table 4). Flushable clean-up items should be
flushed down the toilet. Nonflushable items such as paper
towels should be disposed of in the specified trash bag. If a
caregiver assists with the clean-up, disposable plastic gloves
should be worn during the clean-up process and then dis-
posed of in the specified trash bag.
Stool. During the all restricted periods, patients should
follow these recommendations. Emptying of the bowel mod-
erately reduces radiation to the patient and also to individuals
nearby. To ensure a daily bowel movement, a laxative may be
used.Wiping andflushing should follow the samedirections as
for urination. Also, defecation accidents require the same pre-
cautions for clean-up as described under urinary incontinence.
Saliva. Since 131I concentrations are present in the saliva
for as long as 7 days, patients should avoid kissing, especially
of children, for the period in which sleeping with others is
restricted. Radioactive saliva can contaminate food utensils,
beverages, toothbrushes, sinks, pillowcases, and telephone
mouthpieces, so precautions apply to all of these items.
However, disposable food utensils require special waste con-
siderations; washable utensils are preferable. After eating,
washing food utensils, glassware, and dishes in a dishwasher
or by handwill suffice; the dishesmaybewashedwith those of
the family. If telephone mouthpieces are shared, they should
be wiped carefully after use by the patient or covered with an
easily removed plastic bag. Personal cell phones are preferred.
Blood, wound drainage, and mucus. The following rec-
ommendations apply to the daytime periods of restrictions.
Blood from wounds, epistaxis, menstruation, and other
sources typically contains low levels of radioactivity, but,
nevertheless, requires precautionary clean up; again, anyone
providing assistance should use plastic gloves. Bandages,
clean-up materials, menstrual pads, and gloves should be
disposed of in the specified trash bag. Nasal mucus can also
contain 131I and tissues, unless flushable, should be disposed
of in the specified trash bag.
Perspiration. A small amount of 131I will appear in sweat,
but this could be transferred by hands to the mouths of family
members. Bedding and bed clothes should be handled with
care during the periods that restrict sleeping with another.
Patients should wear disposable plastic gloves if they must
prepare meals for others during the same restricted periods.
Wiping exercise equipment and similar instruments used by
others during the first 48 hours after treatment with flushable
wipes should be sufficient to remove any hazard; the paper
towels and nonflushable clean-up materials should be dis-
posed of in the specified trash bag. Work and/or exercise
clothing that are heavily soiled with perspiration should be
washed immediately or kept away from household members
until laundered. Likewise, bed clothes soiled with perspira-
tion and/or other secretions and should be laundered before
exposure to others.
Vomitus. Nausea occurs frequently and vomiting occa-
sionally, especially in children, after administered activities of
300mCi (11,100MBq) or more (28). The gastric mucosa se-
cretes iodide by the same mechanism as chloride so that
vomitus contains substantial amounts of 131I for days after the
344 SISSON ET AL.
administered activity has been absorbed. Prophylactic anti-
emetics may lessen the gastrointestinal symptoms. For all
periods of restriction, vomitus should be collected using
disposable gloves and preferably, flushed down the toilet;
gloves and nonflushable material, such as paper towels,
should be placed in the specified trash bag.
Specified bag for waste disposal. The specified trash
bags must be leak proof. These bags containing waste can be
returned to the Nuclear Medicine facility after 1 to 2 weeks, as
determined by the respective treatment personnel. Otherwise
the bags should be tightly closed and stored in a secure place
at least 6 feet away from people and animals. The bags can be
taken to the usual household trash disposal sites after 80 days
(10 half lives of 131I) at which time radiation detectors should
not produce alarms.
Summary
Two major principles guide radiation safety: sound medi-
cal practice and adherence to regulations. Therapies with 131I
for thyroid diseases can be performed within NRC regula-
tions by evaluating the requirements for individual patients
and giving advice on reducing radiation exposures through
appropriate and patient-specific precautions. Periodic re-
evaluations of programs and protocols should take into ac-
count the observations on adherence to precautions reported
by patients. An Annotated Summary of the Literature Review
is in the Supplementary Data.
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